First-trimester diagnosis of congenital cytomegalovirus infection after maternal primary infection in early pregnancy: feasibility study of viral genome amplification by PCR on chorionic villi obtained by CVS

V Faure-Bardon, J Fourgeaud, T Guilleminot, J-F Magny, L J Salomon, J-P Bernard, M Leruez-Ville, Y Ville, V Faure-Bardon, J Fourgeaud, T Guilleminot, J-F Magny, L J Salomon, J-P Bernard, M Leruez-Ville, Y Ville

Abstract

Objective: To evaluate the feasibility of amplification of the viral genome by polymerase chain reaction (PCR) analysis of trophoblast samples obtained by chorionic villus sampling (CVS) in cases of maternal primary infection (MPI) with cytomegalovirus (CMV) in early pregnancy.

Methods: This was a prospective study carried out at the Department of Obstetrics and Fetal Medicine, Hopital Necker-E.M., between October 2019 and October 2020. Following CMV serology screening in early pregnancy, CVS was offered to women at 11-14 weeks' gestation after CMV-MPI ≤ 10 weeks. Array-comparative genomic hybridization and amplification of the viral genome by PCR were performed on the trophoblasts obtained by CVS. All cases also underwent amniocentesis from 17 weeks onwards and PCR was performed on the amniotic fluid. Secondary prevention with valacyclovir was initiated as soon as MPI was diagnosed, to decrease the risk of vertical transmission. We evaluated the diagnostic performance of CMV-PCR of trophoblast obtained by CVS, using as the reference standard PCR of amniotic fluid obtained by amniocentesis.

Results: CVS was performed in 37 pregnancies, at a median (range) gestational age of 12.7 (11.3-14.4) weeks. CMV-PCR in chorionic villi was positive in three and negative in 34 cases. CMV-PCR following amniocentesis, performed at a median (range) gestational age of 17.6 (16.7-29.9) weeks, was positive for the three cases which were positive following CVS and, of the 34 patients with a negative finding following CVS, amniocentesis was negative in 31 and positive in three. The sensitivity of CMV-PCR analysis of trophoblast obtained by CVS for the diagnosis of CMV, using as the reference standard PCR analysis of amniotic fluid obtained by amniocentesis, was 50% (95% CI, 19-81%), specificity was 100% (95% CI, 89-100%), positive predictive value was 100% (95% CI, 44-100%) and negative predictive value was 91% (95% CI, 77-97%).

Conclusions: Diagnosis of placental infection following MPI in early pregnancy can be achieved by PCR amplification of the CMV genome in chorionic villi. We propose that negative CMV-PCR in the trophoblast after 12 weeks could be used to exclude CMV-related embryopathy leading to sequelae. However, this needs to be confirmed through long-term follow-up evaluation. These findings could help to establish CVS as the diagnostic test of choice following maternal serology screening in early pregnancy. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.

Keywords: CMV; CVS; amniocentesis; chorionic villus sampling; congenital cytomegalovirus infection; cytomegalovirus; prenatal diagnosis.

© 2021 International Society of Ultrasound in Obstetrics and Gynecology.

References

REFERENCES

    1. Leruez-Ville M, Magny J-F, Couderc S, Pichon C, Parodi M, Bussières L, Guilleminot T, Ghout I, Ville Y. Risk Factors for Congenital Cytomegalovirus Infection Following Primary and Nonprimary Maternal Infection: A Prospective Neonatal Screening Study Using Polymerase Chain Reaction in Saliva. Clin Infect Dis 2017; 65: 398-404.
    1. Faure-Bardon V, Magny J-F, Parodi M, Couderc S, Garcia P, Maillotte A-M, Benard M, Pinquier D, Astruc D, Patural H, Pladys P, Parat S, Guillois B, Garenne A, Bussières L, Guilleminot T, Stirnemann J, Ghout I, Ville Y, Leruez-Ville M. Sequelae of congenital cytomegalovirus following maternal primary infection are limited to those acquired in the first trimester of pregnancy. Clin Infect Dis 2019; 69: 1526-1532.
    1. Foulon I, De Brucker Y, Buyl R, Lichtert E, Verbruggen K, Piérard D, Camfferman FA, Gucciardo L, Gordts F. Hearing Loss With Congenital Cytomegalovirus Infection. Pediatrics 2019; 144: e20183095.
    1. Chatzakis C, Ville Y, Makrydimas G, Dinas K, Zavlanos A, Sotiriadis A. Timing of primary maternal cytomegalovirus infection and rates of vertical transmission and fetal consequences. Am J Obstet Gynecol 2020; 223: 870-883.e11.
    1. Vauloup-Fellous C, Berth M, Heskia F, Dugua J-M, Grangeot-Keros L. Re-evaluation of the VIDAS® cytomegalovirus (CMV) IgG avidity assay: Determination of new cut-off values based on the study of kinetics of CMV-IgG maturation. J Clin Virol 2013; 56: 118-123.
    1. Delforge ML, Desomberg L, Montesinos I. Evaluation of the new LIAISON® CMV IgG, IgM and IgG Avidity II assays. J Clin Virol 2015; 72: 42-45.
    1. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007; 17: 253-276.
    1. Shahar-Nissan K, Pardo J, Peled O, Krause I, Bilavsky E, Wiznitzer A, Hadar E, Amir J. Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: a randomised, double-blind, placebo-controlled trial. Lancet 2020; 396: 779-785.
    1. Pass RF, Fowler KB, Boppana SB, Britt WJ, Stagno S. Congenital cytomegalovirus infection following first trimester maternal infection: symptoms at birth and outcome. J Clin Virol 2006; 35: 216-220.
    1. Enders M, Daiminger A, Exler S, Ertan K, Enders G, Bald R. Prenatal diagnosis of congenital cytomegalovirus infection in 115 cases: a 5 years' single center experience. Prenat Diagn 2017; 37: 389-398.
    1. Ville Y. What is new in infection in pregnancy. Presentation at ECCI, 13-14 November 2020, Online congress. .
    1. Leruez-Ville M, Ghout I, Bussières L, Stirnemann J, Magny J-F, Couderc S, Salomon LJ, Guilleminot T, Aegerter P, Benoist G, Winer N, Picone O, Jacquemard F, Ville Y. In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study. Am J Obstet Gynecol 2016; 215: 462.e1-10.
    1. Pereira L. Congenital Viral Infection: Traversing the Uterine-Placental Interface. Annu Rev Virol 2018; 5: 273-299.
    1. Society for Maternal-Fetal Medicine (SMFM), Hughes BL, Gyamfi-Bannerman C. Diagnosis and antenatal management of congenital cytomegalovirus infection. Am J Obstet Gynecol 2016; 214: B5-B11.
    1. NHS. UK Standards for Microbiology Investigations. Investigation of cytomegalovirus infection. Issued by the Standards Unit, National Infection Service, Public Health England (PHE) Virology | V 28 | Issue no: 4. . Issued June 26, 2019.
    1. Diagnostic par sérologie et/ou par recherche du génome viral de l'infection congénitale à cytomégalovirus. Haute Autorité de Santé. [Accessed February 10, 2020] .
    1. Leruez-Ville M, Foulon I, Pass R, Ville Y. Cytomegalovirus infection during pregnancy: state of the science. Am J Obstet Gynecol 2020; 223: 330-349.
    1. Bilavsky E, Pardo J, Attias J, Levy I, Magny J-F, Ville Y, Leruez-Ville M, Amir J. Clinical Implications for Children Born With Congenital Cytomegalovirus Infection Following a Negative Amniocentesis. Clin Infect Dis 2016; 63: 33-38.
    1. Leruez-Ville M, Ville Y. Fetal cytomegalovirus infection. Best Pract Res Clin Obstet Gynaecol 2017; 38: 97-107.
    1. Gabrielli L, Bonasoni MP, Santini D, Piccirilli G, Chiereghin A, Guerra B, Landini MP, Capretti MG, Lanari M, Lazzarotto T. Human fetal inner ear involvement in congenital cytomegalovirus infection. Acta Neuropathol Commun 2013; 1: 63.
    1. Teissier N, Delezoide A-L, Mas A-E, Khung-Savatovsky S, Bessières B, Nardelli J, Vauloup-Fellous C, Picone O, Houhou N, Oury J-F, Van Den Abbeele T, Gressens P, Adle-Biassette H. Inner ear lesions in congenital cytomegalovirus infection of human fetuses. Acta Neuropathol 2011; 122: 763-774.
    1. López M, Coll O. Chronic Viral Infections and Invasive Procedures: Risk of Vertical Transmission and Current Recommendations. Fetal Diagn Ther 2010; 28: 1-8.
    1. Malan V, Bussières L, Winer N, Jais JP, Baptiste A, Le Lorc'h M, Elie C, O'Gorman N, Fries N, Houfflin-Debarge V, Sentilhes L, Vekemans M, Ville Y, Salomon LJ; SAFE 21 Study Group. Effect of Cell-Free DNA Screening vs Direct Invasive Diagnosis on Miscarriage Rates in Women With Pregnancies at High Risk of Trisomy 21: A Randomized Clinical Trial. JAMA 2018; 320: 557-565.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅